Porcine PERT

DRUG3 trials

Sponsors

Anthera Pharmaceuticals, Entero Therapeutics

Conditions

Cystic FibrosisCystic Fibrosis (CF)Exocrine Pancreatic InsufficiencyExocrine Pancreatic Insufficiency (EPI)

Phase 2

OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

CompletedNCT03746483

Entero TherapeuticsCystic Fibrosis (CF), Exocrine Pancreatic Insufficiency (EPI)

Start: 2019-01-10End: 2019-07-27Updated: 2022-06-06

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

CompletedNCT04375878

Entero TherapeuticsCystic Fibrosis (CF), Exocrine Pancreatic Insufficiency (EPI)

Start: 2020-07-20End: 2021-04-08Updated: 2022-09-13

Phase 3

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Anthera PharmaceuticalsCystic Fibrosis, Exocrine Pancreatic Insufficiency

Start: 2017-04-28End: 2018-06-30Target: 140Updated: 2018-03-08